The HALT-IT trial is assessing whether early administration of tranexamic acid in people with acute gastrointestinal bleeding can reduce their risk of dying in the hospital. The trial is also measuring the effects of the treatment on re-bleeding, non-fatal vascular events, blood transfusion, surgical intervention and general health status. The HALT-IT trial began recruitment on 4 July 2013 and is aiming to recruit 8,000 patients from hospital worldwide by 30 November 2017.

Gastrointestinal bleeding is a common emergency with a 10-15% death rate. An effective treatment could save thousands of lives worldwide, In the CRASH-2 trial, we showed that, if given within 1 hour, tranexamic acid reduces mortality in bleeding trauma patients. Specifically, tranexamic acid reduces the risk of bleeding to death by about one third, with no increase in side effects. If tranexamic acid was shown to have similar effects in gastrointestinal bleeding, this would be a major advance.

6059 patients randomised 
(last updated 20/01/2017) 

  • The Principal Investigator at Queen Elizabeth Hospital (QEH), Birmingham Dr Elaine Hardy has an excellent team working on the HALT-IT trial. She explains how the trial has been so successful at QEH.

    Read Post
  • To celebrate exceeding the 3000 patient milestone, HALT-IT has now published the Summer 2015 newsletter to credit the collaborators and acknowledge this amazing achievement! View the newsletter here.

    Read Post
  • HALT-IT Research Nurses at Royal Stoke University Hospital and Leicester Royal Infirmary explain how they have improved their recruitment by 10 patients in 6 weeks!

    Read Post